|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01558 HEC CJ PHARM
Nominal 
9.600 +0.210 (+2.236%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 2,454,762 | -23.504% | 3,209,002 | 1,293,308 | 202,246 | 2,083,705 |
| Cost of Sales | (505,530) | -21.631% | (645,065) | (332,651) | (101,458) | (352,864) |
| Gross Profit | 1,949,232 | -23.975% | 2,563,937 | 960,657 | 100,788 | 1,730,841 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 813,531 | -35.529% | 1,261,853 | (36,402) | (588,204) | 757,836 | |
| Taxation | (128,800) | -45.866% | (237,929) | 3,940 | 81,227 | (141,095) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 5,571 | (336) | (51) | 767 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 684,731 | -33.489% | 1,029,495 | (32,798) | (507,028) | 617,508 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 7,424 | -93.048% | 106,784 | 133,839 | 111,183 | 109,097 |
| Depreciation & Amortisation | 196,838 | 2.038% | 192,907 | 174,065 | 115,188 | 49,354 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 78.000 | -33.333% | 117.000 | -4.000 | -58.000 | 70.000 |
| DPS (cts) | 135.820 | -- | 0.000 | 0.000 | 0.000 | 10.000 |
| Dividend Payout Ratio (%) | 174.129% | -- | -- | -- | -- | 14.286% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 9.847 | -- | 7.858 | 6.563 | 4.982 | 5.409 |
| Remarks: | Real time quote last updated: 15/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 684,731 |
| %Change | -33.489% |
| EPS / (LPS) | RMB 0.780 |
| NBV Per Share (¥) | RMB 9.847 |